Assertio (NASDAQ:ASRT) Therapeutics, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company focused on developing and commercializing treatments for patients with chronic and rare disorders. The company’s core areas of expertise include neurology, pain management and migraine prevention. With a portfolio of both marketed therapies and pipeline assets, Assertio seeks to address unmet medical needs through targeted drug delivery and strategic partnerships.
Assertio’s marketed products include Gralise, an extended-release formulation of gabapentin for post-herpetic neuralgia; Zipsor, a topical diclofenac epolamine gel designed for the treatment of acute pain; and Cambia, a diclofenac potassium powder for oral suspension indicated for acute migraine attacks. In addition, the company has advanced Qulipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, through regulatory approval for the preventive treatment of episodic migraine. These therapies reflect Assertio’s commitment to offering differentiated dosage forms and improved patient convenience.
Originally founded in 1995 as Depomed, the organization rebranded to Assertio Therapeutics in 2017 to underscore its sharpened focus on neurological and pain indications. Headquartered in Naperville, Illinois, the company operates across the United States and collaborates with global partners to extend the reach of its products. Assertio’s commercial strategy combines direct sales with licensing agreements, enabling access to a broader patient population while leveraging the marketing capabilities of international pharmaceutical firms.
Under the leadership of a seasoned executive team, including co-founder and Chief Executive Officer Ray Berger, Assertio continues to pursue growth through both in-license opportunities and internal research programs. The company’s research and development efforts aim to expand its pipeline in migraine prevention and other neurological conditions, with an emphasis on innovation in drug delivery systems. Assertio’s strategic initiatives are supported by a governance framework that prioritizes clinical excellence and value creation for patients and stakeholders alike.
